报价延迟最少15分钟:2026/04/14 16:39 EDT
盘后时段
|
||||
|
8.59 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.59
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-58.66/-4.23
|
|
企业价值
54.53M
|
| 资产负债 |
|
每股账面净值
6.10
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
43.77M
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Itsintegrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases. |
